

**MEDIA CONTACT:**

**Eisai Co., Ltd.**  
Public Relations Department  
+81.3.3817.5120

**MEDIA CONTACT:**

**Biogen Idec**  
Kate Niazi-Sai  
+1.781.464.3260  
[public.affairs@biogenidec.com](mailto:public.affairs@biogenidec.com)

**INVESTOR CONTACTS:**

**Biogen Idec**  
Claudine Prowse, Ph.D.  
+1.781.464.2442  
[IR@biogenidec.com](mailto:IR@biogenidec.com)

Carlo Tanzi, Ph.D.  
+1.781.464.2442  
[IR@biogenidec.com](mailto:IR@biogenidec.com)

**EISAI AND BIOGEN IDEC ENTER COLLABORATION TO DEVELOP  
AND COMMERCIALIZE DISEASE TREATMENTS**

*- Agreement to Enhance R&D Capabilities and Pipeline Aimed at Creating New Therapies to Suppress  
Alzheimer's Disease Progression -*

**TOKYO and CAMBRIDGE, Mass. March 5, 2014** [Eisai Co., Ltd.](#) (TSE: 4523) and [Biogen Idec](#) (NASDAQ: BIIB) announced today that they have entered into a collaboration to develop and commercialize two of Eisai's clinical candidates for Alzheimer's disease (AD), E2609 and BAN2401. The agreement also provides Eisai with an option to jointly develop and commercialize two of Biogen Idec's candidates for AD, the anti-amyloid beta (A $\beta$ ) antibody BIIB037 and an anti-tau monoclonal antibody.

The collaboration initially will be centered on the co-development and co-commercialization of Eisai's two candidates: E2609, a  $\gamma$ -site amyloid precursor protein cleaving enzyme (BACE) inhibitor, and BAN2401, an anti-A $\beta$  antibody. These candidates have the potential to reduce A $\beta$  plaques that

additional one-time payment from Biogen Idec related to joint development and commercialization activities in Japan.

